NCT02718430已完成1 期
VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis Under Second or Third Line Therapy to Examine Safety, Efficacy, and Immune Biomarkers After Treatment With VXM01
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Vaximm GmbH
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Safety and tolerability taking into account treatment-limiting toxicities (TLTs)
研究概览
简要总结
Phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent, including liver metastasis biopsy, signed and dated
- •Histologically or cytologically confirmed colorectal cancer, excluding primary tumors of appendiceal origin (participants are eligible to enroll irrespective of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status)
- •Male or female patients who must be post-menopausal for at least 2 years or surgically sterile.
- •Confirmed metastatic colorectal cancer (Stage IV)
- •Presence of non-resectable liver metastasis
- •Accessibility of liver metastasis appropriate for biopsy sampling
- •Adequate coagulation parameters including platelet count ≥100,000/mm3
- •Absence of concomitant medication which could represent a contraindication for biopsy (e.g., anti-platelet drugs including aspirin, ticlopidine, clopidogrel, IIb/IIIa receptor antagonists, non-steroidal anti-inflammatory drugs [NSAIDs], and vitamin K antagonist anticoagulants)
- •The participant has received first-line irinotecan- or oxaliplatin-based therapy without or in combination with a targeted antibody for metastatic disease and a) Experienced radiographic disease progression during first-line therapy, or b) Experienced radiographic disease progression ≤ 6 months after the last dose of first-line therapy, or c) Discontinued part or all of first-line therapy due to toxicity and experienced radiographic disease progression ≤ 6 months after the last dose of first-line therapy
- •Receipt of no more than 3 prior systemic therapy regimen for metastatic disease
- •Measurable or non-measurable disease based on the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v. 1.1)
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •Life expectancy > 3 months
- •Adequate renal, hepatic, and bone marrow function
- •Leukocytes ≥4.0 x 109 / L
- •Absolute neutrophil count (ANC) > 1,500/mm3
- •Platelet count ≥ 100,000/mm3
- •Hemoglobin ≥ 9 g/dL (can be post-transfusion)
- •International normalized ratio (INR) ≤ 1.5
- •Activated partial thromboplastin time (aPTT) ≤ 1.5 times upper limit of normal (ULN)
- •Bilirubin ≤ 1.5 times ULN
- •ALT and AST ≤ 2.5 times ULN
- •Creatinine ≤ 2.0 mg/dL
- •Proteinuria ≤ 1+ by urine dipstick OR ≤ 1 g by 24-hour urine collection
- •Patients who are able to understand the nature and purpose of the study including possible risks, willing to comply with the requirements, and to provide their written informed consent to participate in the study
排除标准
- •Concomitant treatment with anti-angiogenic therapy before progression of disease
- •Treatment in any other clinical trial within 30 days before screening.
- •Gastric bypass
- •Other anatomical change of the gastrointestinal tract, interfering with gastrointestinal passage, except colostoma or colon bypass
- •Untreated CNS metastases. Participants with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation ending at least 2 weeks prior to randomization, or after surgical resection performed at least 28 days prior to randomization. No evidence of Grade greater than or equal to 1 CNS hemorrhage based on pretreatment Magnetic Resonance Imaging (MRI) or intravenous (IV) contrast CT scan
- •Significant traumatic injury or surgery within the past 4 weeks
- •Cerebrovascular accident, transient ischemic attack, or subarachnoid hemorrhage within the past 6 months
- •Other malignancies within the past 5 years except for adequately treated carcinoma in situ of the cervix, and/or basal cell skin cancer, and/or early endometrial carcinoma
- •Pre-existing sensory or motor neuropathy ≥ grade 2
- •History or evidence of CNS disease (e.g., uncontrolled seizures) by neurological examination unless adequately treated with standard medical therapy
- •History or evidence of thrombotic or hemorrhagic disorders, including intracranial hemorrhage
- •Uncontrolled hypertension (i.e., blood pressure > 160/100 mm Hg)
- •Clinically significant cardiovascular disease, including any of the following:
- •Myocardial infarction or unstable angina within the past 6 months
- •New York Heart Association class III-IV congestive heart failure
- •Poorly controlled cardiac arrhythmia despite medication, except rate controlled atrial fibrillation
- •Peripheral vascular disease ≥ grade 3 (i.e., symptomatic and interfering with activities of daily living requiring repair or revision)
- •Positive for anti-typhoid IgG/IgM antibodies according to the onsite test on Day 0
- •Hemoptysis within 6 months before randomization
- •Esophageal varices
- •Upper or lower gastrointestinal bleeding within 6 months before randomization
- •Non-healing wound, incomplete wound healing, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion
- •Gastrointestinal fistula
- •Thrombolysis therapy within 4 weeks before randomization
- •Presence of any acute or chronic systemic infection
- •Major surgical procedures, or open biopsy within 4 weeks before randomization
- •Chronic concurrent therapy within 2 weeks before and during the initial treatment period (Day 1 to Day 7):
- •Corticosteroids (except steroids for adrenal failure or emesis prophylaxis up to 4 mg daily dose) or immunosuppressive agents
- •Antibiotics
- •Bevacizumab or any other anti-angiogenic treatment
- •Known multi-drug resistant gram-negative bacteria
- •History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications
- •Women of childbearing potential
研究组 & 干预措施
VXM01
Experimental
VXM01 10E6 or 10E7 CFU
干预措施: VXM01 (Drug)
结局指标
主要结局
Safety and tolerability taking into account treatment-limiting toxicities (TLTs)
时间窗: 18 months
AEs listed together with information on onset, duration, severity, seriousness, relationship to the study drug, relationship to chemotherapy and to the underlying disease, outcome, and action taken. Frequency tables by System Organ Class and preferred term.
次要结局
- Immune Response by Enzme Linked Immuno Spot (ELISpot)(18 months)
- Immune biomarker by tumor tissue immunohistochemistry staining(66 days)
- Serum biomarker Response by Enzyme Linked Immuno Sorbent Assay (ELISA)(18 months)
- Biodistribution and shedding of VXM01(10 days)
- Clinical Response including tumor staging according to the response criteria in solid tumors (RECIST)(18 months)
- Tumor vasculature by tumor tissue immunohistochemistry staining(66 days)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
TATE and Pembrolizumab (MK3475) in mCRC and NSCLCColorectal Cancer Lung CancerNCT04701476Teclison Ltd.110
终止
1 期
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)Colorectal Neoplasms MalignantNCT04873895Abramson Cancer Center at Penn Medicine5
已完成
1 期
Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI).Colorectal Cancer MetastaticNCT02350400Singapore General Hospital5
已完成
不适用
An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver MetastasesColorectal CancerNCT01343901Hoffmann-La Roche210
Unknown
2 期
Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLMColorectal Cancer Liver MetastasesNCT05485909Sun Yat-sen University32